{"id":12934,"date":"2021-10-12T12:37:11","date_gmt":"2021-10-12T10:37:11","guid":{"rendered":"https:\/\/lombardialifesciences.it\/horizon-europe-cluster-health-pubblica-i-nuovi-bandi-destination-3\/"},"modified":"2023-06-22T22:14:34","modified_gmt":"2023-06-22T20:14:34","slug":"horizon-europe-cluster-health-pubblica-i-nuovi-bandi-destination-3","status":"publish","type":"post","link":"https:\/\/lombardialifesciences.it\/en\/horizon-europe-cluster-health-pubblica-i-nuovi-bandi-destination-3\/","title":{"rendered":"Horizon Europe: cluster HEALTH pubblica i nuovi bandi Destination 3"},"content":{"rendered":"<p>L\u2019obiettivo del\u00a0cluster <a href=\"https:\/\/www.lombardialifesciences.it\/news\/salute-pubblicato-il-programma-di-lavoro-2021-2022-di-horizon-europe\/\"><strong>Health<\/strong>\u00a0<\/a>\u00e8 rispondere alle principali\u00a0<strong>sfide sanitarie della societ\u00e0 contemporanea<\/strong>\u00a0per proteggere la salute e il benessere dei cittadini di ogni et\u00e0, sviluppando soluzioni innovative e tecnologie sanitarie per la prevenzione, il monitoraggio e il trattamento di disturbi e patologie. La ricerca e l\u2019innovazione sono anche fondamentali per comprendere gli effetti a lungo termine del\u00a0<strong>Covid-19<\/strong>\u00a0e per sviluppare risposte efficaci per una solida ripresa dell&#8217;Unione.<\/p>\n<p><strong>Destination 3 \u2013 Tackling diseases and reducing disease burden<\/strong>\u00a0ha l&#8217;obiettivo di migliorare la comprensione e il trattamento delle malattie, rendere le tecnologie sanitarie pi\u00f9 efficaci e innovative, migliorare la capacit\u00e0 e la preparazione per gestire i focolai epidemici e per una maggiore sicurezza dei pazienti.<\/p>\n<p>Il bando <strong><a href=\"https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/portal\/screen\/opportunities\/topic-search;callCode=HORIZON-HLTH-2022-DISEASE-06-two-stage;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;programmePeriod=null;programCcm2Id=43108390;programDivisionCode=43108557;focusAreaCode=null;destination=43650669;mission=null;geographicalZonesCode=null;programmeDivisionProspect=null;startDateLte=null;startDateGte=null;crossCuttingPriorityCode=null;cpvCode=null;performanceOfDelivery=null;sortQuery=sortStatus;orderBy=asc;onlyTenders=false;topicListKey=callTopicSearchTableState\" target=\"_blank\" rel=\"noopener\">Tackling diseases (Two Stage &#8211; 2022)<\/a><\/strong> contiene <strong>3 topic<\/strong>, per un budget complessivo ad essi destinati pari a<strong>\u00a0160 milioni di \u20ac<\/strong>:<\/p>\n<ul>\n<li><a href=\"https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/portal\/screen\/opportunities\/topic-details\/horizon-hlth-2022-disease-06-02-two-stage;callCode=HORIZON-HLTH-2022-DISEASE-06-two-stage;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;programmePeriod=null;programCcm2Id=43108390;programDivisionCode=43108557;focusAreaCode=null;destination=43650669;mission=null;geographicalZonesCode=null;programmeDivisionProspect=null;startDateLte=null;startDateGte=null;crossCuttingPriorityCode=null;cpvCode=null;performanceOfDelivery=null;sortQuery=sortStatus;orderBy=asc;onlyTenders=false;topicListKey=callTopicSearchTableState\" target=\"_blank\" rel=\"noopener\">HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs<\/a>\u00a0(RIA), con un budget di 60 milioni di \u20ac<\/li>\n<li><a href=\"https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/portal\/screen\/opportunities\/topic-details\/horizon-hlth-2022-disease-06-03-two-stage;callCode=HORIZON-HLTH-2022-DISEASE-06-two-stage;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;programmePeriod=null;programCcm2Id=43108390;programDivisionCode=43108557;focusAreaCode=null;destination=43650669;mission=null;geographicalZonesCode=null;programmeDivisionProspect=null;startDateLte=null;startDateGte=null;crossCuttingPriorityCode=null;cpvCode=null;performanceOfDelivery=null;sortQuery=sortStatus;orderBy=asc;onlyTenders=false;topicListKey=callTopicSearchTableState\" target=\"_blank\" rel=\"noopener\">HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 &#8211; developing the next generation of vaccines<\/a>\u00a0(RIA), con un budget di 40 milioni di \u20ac<\/li>\n<li><a href=\"https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/portal\/screen\/opportunities\/topic-details\/horizon-hlth-2022-disease-06-04-two-stage;callCode=HORIZON-HLTH-2022-DISEASE-06-two-stage;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;programmePeriod=null;programCcm2Id=43108390;programDivisionCode=43108557;focusAreaCode=null;destination=43650669;mission=null;geographicalZonesCode=null;programmeDivisionProspect=null;startDateLte=null;startDateGte=null;crossCuttingPriorityCode=null;cpvCode=null;performanceOfDelivery=null;sortQuery=sortStatus;orderBy=asc;onlyTenders=false;topicListKey=callTopicSearchTableState\" target=\"_blank\" rel=\"noopener\">HORIZON-HLTH-2022-DISEASE-06-04-two-stage: Development of new effective therapies for rare diseases<\/a>\u00a0(RIA), con un budget di 60 milioni di \u20ac<\/li>\n<\/ul>\n<p>Tutti i topic hanno una modalit\u00e0 di presentazione e\u00a0<strong>valutazione a due fasi<\/strong>: la scadenza per inviare le short proposal\u00a0\u00e8 il\u00a0<strong>1\u00b0 febbraio 2022<\/strong>, mentre la scadenza per inviare le full proposal \u00e8 il <strong>6 settembre 2022<\/strong>.<\/p>\n<p>Il WP 2021-2022 relativo al Cluster HEALTH pu\u00f2 esser consultato al seguente <a href=\"https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/docs\/2021-2027\/horizon\/wp-call\/2021-2022\/wp-4-health_horizon-2021-2022_en.pdf\">link<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019obiettivo del\u00a0cluster Health\u00a0\u00e8 rispondere alle principali\u00a0sfide sanitarie della societ\u00e0 con&#8230;<\/p>\n","protected":false},"author":1,"featured_media":12620,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[44],"tags":[76,111,130,129],"class_list":["post-12934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-bandi","tag-finanziamenti","tag-horizon-europe","tag-salute"],"acf":[],"_links":{"self":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/12934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/comments?post=12934"}],"version-history":[{"count":1,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/12934\/revisions"}],"predecessor-version":[{"id":17598,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/12934\/revisions\/17598"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/media\/12620"}],"wp:attachment":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/media?parent=12934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/categories?post=12934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/tags?post=12934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}